Behavioral and rewarding effects of methylone, an analog of MDMA in mice

Hirosaki Medical Journal

Volumn 62, Issue 1, 2011, Pages 56-71

  Miyazawa, Maki ^a,b   Kojima, Takashi ^b   Nakaji, Shigeyuki ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

FosB; Behavioral effect; MDMA; Methylone; Rewarding effect

Indexed keywords

EID: 79958740730     PISSN: 04391721     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ricaurte GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet 2005;365:2137-2145. (Pubitemid 40826972)
2. Cami J, Farré M, Mas M. Roset PN, Poudevida S, Mas A, San L, et al. Human pharmacology of 3,4 -methylenedioxymethamphetamine ("ecstasy") : psychomotor performance and subjective effects. J Clin Psychopharmacol 2000;20:455-466. (Pubitemid 30463762)
3. Bossong MG, Van Dijk JP, Niesink RJ. Methylone and mCPP, two new drugs of abuse? Addict Biol 2005;10:321-323. (Pubitemid 41759265)
4. Yasuda I. The identification of illegal drugs and the change of circulation products. Ann Rep Tokyo Metr Inst Pub Health 2007:58:3745.
5. McNamara S, Stokes S, Coleman N. Head shop compound abuse amongst attendees of the Drug Treatment Centre Board. Ir Med J 2010:103:136-137.
6. Kojima T, Miyazawa M, Doi K. Restriction in the future of uncontrolled substances. Modern Media 2006:52:99-108.
7. Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R, Hashimoto K. Combined intoxication with methylone and 5-MeO-MIPT. Progr Neuro-psychopharmacol Biol Psychiatry 2007;31:288-291. (Pubitemid 44959240)
8. Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, Katagi M, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 2006;36:709-723. (Pubitemid 44195985)
9. Cozzi NV, Sievert MK, Shulgin AT, Jcob P 3rd, Ruoho AE. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 1999;381:63-9. (Pubitemid 29488590)
10. Nagai F, Nonaka R, Satoh H, Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007;559:132-137. (Pubitemid 46295399)
11. Nakagawa Y, Suzuki T, Tayama S, Ishii H, Ogata A. Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch Toxicol 2009;83:69-80.
12. Dal Cason TA, Young R, Glennon RA. Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 1997;58:1109-1116. (Pubitemid 28108223)
13. Nestler EJ, Barrot M, Self DW. A FosB: Asustained molecular switch for addiction. Proc Natl Acad Sci USA 2001;98:11042-11046.
14. Irwin S. Comprehensive observational Assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968;13:222-257.
15. Moser VC, Becking GC, MacPhail RC, Ruling BM. The IPCS collaborative study on neurobehavioral screening methods. Fundam Appl Toxicol 1997; 35:143-151.
16. Noda Y, Miyamoto Y, Mamiya T, Kamei H, Furukawa H, Nabeshima T. Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. J Pharmacol Exp Ther 1998:286:44-51. (Pubitemid 28317972)
17. Funada M. Evaluation of the rewarding effect of drug by conditioned place preference paradigm: its bases and applications. Folia Pharmacol Jpn 2005;126:10-16. (Pubitemid 41008478)
18. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. 2nd ed. San Diado; Academic press; 2001.
19. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994;13:1235-1244. (Pubitemid 24372141)
20. Chen J, Nye HE, Kelz MB, Hiroi N, Nakabeppu Y, Hope BT, Nestler EJ. Regulation of delta FosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol Pharmacol 1995;48:880-889. (Pubitemid 3015243)
21. Hiroi N, Brown JR, Haile CN, Ye H, Greenberg ME, Nestler EJ. FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA 1997:94:10397-10402. (Pubitemid 27407053)
22. Alibhai IN, Green TA, Potashkin JA, Nestler EJ. Regulation of fosB and DeltafosB mRNA expression: in vivo and in vitro studies. Brain Res 2007; 27:22-33. (Pubitemid 46440806)
23. Satoh K, Fukumori N, Nonaka R, Fuwa T, Tanaka T. Development of assay systems to detect and evaluate the biological effects of (potentially) illegal drugs. Ann. Rep. Tokyo Metr Inst Pub Health 2009;60:21-35.
24. Wall SC, Gu H, Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 1995:47:544-550.
25. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev. 2003:55:463-508. (Pubitemid 37013213)
26. Bilsky EJ, Hui YZ, Hubbell CL, Reid LD. Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of an alcoholic beverage. Pharmacol Biochem Behav 1990:37:633-638.
27. Salzmann J, Marie-Claire C, Le Guen S, Roques BP, Noble F. Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. Br J Pharmacol 2003;140:831-838. (Pubitemid 37464064)
28. Nye HE, Nestler EJ. Induction of chronic Fosrelated antigens in rat brain by chronic morphine administration. Mol Pharmacol 1996:49:636-45. (Pubitemid 26117147)
29. Murphy CA, Russig H, Pezze MA, Ferger B, Feldon J. Amphetamine withdrawal modulates FosB expression in mesolimbic dopaminergic target nuclei: effects of different schedules of administration. Neuropharmacology 2003:44:929-939.
30. McDaid J, Graham MP, Napier TC. Methamphetamine-induced sensitization differentially alters pCREB and Δ-FosB throughout the limbic circuit of the mammalian brain. Mol Pharmacol 2006:70:2064-2074. (Pubitemid 44771922)
31. Olausson P, Jentsch JD, Tronson N, Neve RL, Nestler EJ, Taylor JR. DeltaFosB in the nucleus accumbens regulates food-reinforced instrumental behavior and motivation. J Neurosci 2006:26:9196-9204. (Pubitemid 44359846)
32. Perrotti LI, Weaver RR, Robison B, Renthal W, Maze I, Yazdani S, Elmore RG, et al. Distinct patterns of deltaFosB induction in brain by drugs of abuse. Synapse 2008;62:358-369. (Pubitemid 351451804)
33. Nakabeppu Y, Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 1991;64:751-759. (Pubitemid 121001162)
34. Kelz MB, Chen J, Carlezon WA Jr, Whisler K, Gilden L, Beckmann AM, Steffen C, et al. Expression of the transcription factor DFosB in the brain controls sensitivity to cocaine. Nature 1999; 401:272-276.
35. Bibb JA, Chen J, Taylor JR, Svenningsson P, Nishi A, Snyder GL, Yan Z, et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 2001;410:376-380. (Pubitemid 32246055)
36. Renthal W, Carle TL, Maze I, Covington HE 3rd, Truong HT, Alibhai I, Kumar A, et aL Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure. J Neurosci 2008;28:7344-7349.